<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Peptide2Mol: A Diffusion Model for Generating Small Molecules as Peptide Mimics for Targeted Protein Binding - Health AI Hub</title>
    <meta name="description" content="Peptide2Mol presents an E(3)-equivariant graph neural network diffusion model designed to generate small molecules that function as peptide mimics for targeted ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Peptide2Mol: A Diffusion Model for Generating Small Molecules as Peptide Mimics for Targeted Protein Binding</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.04984v1" target="_blank">2511.04984v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-07
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Xinheng He, Yijia Zhang, Haowei Lin, Xingang Peng, Xiangzhe Kong, Mingyu Li, Jianzhu Ma
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.04984v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="http://arxiv.org/pdf/2511.04984v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">Peptide2Mol presents an E(3)-equivariant graph neural network diffusion model designed to generate small molecules that function as peptide mimics for targeted protein binding. By referencing both endogenous peptide binders and their surrounding protein pocket environments, the model aims to improve upon AI-driven drug design by explicitly considering critical protein-peptide interactions. It achieves state-of-the-art generative performance and enables molecule optimization and peptidomimetic design through a partial diffusion process.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant to medical advancements by providing a novel, AI-driven approach to discover and optimize small molecule drug candidates that mimic natural peptide interactions, potentially leading to more potent, selective, and orally bioavailable therapeutics for a wide range of diseases.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The Peptide2Mol model is an E(3)-equivariant graph neural network diffusion model, a type of artificial intelligence, applied to generate and optimize small molecules. These AI-generated molecules are designed to mimic peptides and bind specifically to protein targets, serving as potential drug candidates. This application of AI directly aims to accelerate and improve the efficiency of the early stages of drug discovery and development for medical treatments.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the limitation of current AI drug design neglecting endogenous protein-peptide interactions, which can lead to suboptimal molecule designs.</li>
                    
                    <li>Introduces Peptide2Mol, an E(3)-equivariant graph neural network (GNN) diffusion model for small molecule generation.</li>
                    
                    <li>Generates small molecules by simultaneously referencing original peptide binders and their surrounding protein pocket environments.</li>
                    
                    <li>Utilizes a diffusion process for non-autoregressive generation of new molecular structures.</li>
                    
                    <li>Achieves state-of-the-art (SOTA) performance in non-autoregressive generative tasks.</li>
                    
                    <li>Produces molecules demonstrating similarity to the original peptide binders, facilitating peptidomimetic design.</li>
                    
                    <li>Enables molecule optimization and peptidomimetic design through a specific partial diffusion process.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>Peptide2Mol employs an E(3)-equivariant graph neural network operating within a diffusion model framework. It is trained on large datasets to learn the complex relationship between peptide binders, protein pocket environments, and small molecule structures. The generation process involves a diffusion mechanism that allows for non-autoregressive synthesis of molecules, with a partial diffusion capability enabling iterative molecule optimization and the direct design of peptidomimetics.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The model demonstrates state-of-the-art performance in non-autoregressive generative tasks. A crucial finding is its ability to generate small molecules that exhibit structural similarity to the original peptide binders, directly supporting the creation of peptidomimetics. Furthermore, the partial diffusion process was found to be effective for targeted molecule optimization, enhancing its utility in drug development workflows.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>Peptide2Mol has the potential to significantly accelerate the identification and optimization of hit and lead compounds in drug discovery pipelines. By generating high-quality, peptide-mimicking small molecules with improved binding profiles, it could reduce the time and cost associated with preclinical drug development, ultimately bringing more effective and safer therapeutic agents to patients faster.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly mention specific limitations of the Peptide2Mol model or its current application.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract does not explicitly mention future research directions, though implied applications include further validation and expansion to a broader range of therapeutic targets.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Targeted Therapy</span>
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Immunology</span>
                    
                    <span class="tag">Infectious Diseases</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Peptide mimics</span>
                    
                    <span class="tag tag-keyword">Peptidomimetics</span>
                    
                    <span class="tag tag-keyword">Drug design</span>
                    
                    <span class="tag tag-keyword">Diffusion model</span>
                    
                    <span class="tag tag-keyword">Graph neural network</span>
                    
                    <span class="tag tag-keyword">Protein binding</span>
                    
                    <span class="tag tag-keyword">Small molecule generation</span>
                    
                    <span class="tag tag-keyword">Structure-based drug design</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Structure-based drug design has seen significant advancements with the
integration of artificial intelligence (AI), particularly in the generation of
hit and lead compounds. However, most AI-driven approaches neglect the
importance of endogenous protein interactions with peptides, which may result
in suboptimal molecule designs. In this work, we present Peptide2Mol, an
E(3)-equivariant graph neural network diffusion model that generates small
molecules by referencing both the original peptide binders and their
surrounding protein pocket environments. Trained on large datasets and
leveraging sophisticated modeling techniques, Peptide2Mol not only achieves
state-of-the-art performance in non-autoregressive generative tasks, but also
produces molecules with similarity to the original peptide binder.
Additionally, the model allows for molecule optimization and peptidomimetic
design through a partial diffusion process. Our results highlight Peptide2Mol
as an effective deep generative model for generating and optimizing bioactive
small molecules from protein binding pockets.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>Abstract 1 page, main text 9 pages, references 2 pages, 4 figures.
  Submitted to RECOMB 2026</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>